Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson
Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD ...
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Is Gilead Sciences Gaining or Losing Market Support?
Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Gilead Sciences's Options: A Look at What the Big Money is Thinking
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Healio15h
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
The Financial Express1d
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To
We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...
Le Lézard22h
Gilead Sciences - Women's History Month Celebrated With Its Team
NORTHAMPTON, MA / ACCESS Newswire / March 14, 2025 / In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her ...
Fierce Pharma3d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $130.00
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...